title: Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of PCOS patients.
  
  
  METHODS
  Controlled clinical study.
  
  
  METHODS
  PCOS patients in a clinical research environment.
  
  
  METHODS
  20 overweight PCOS patients were enrolled after informed consent.
  
  
  METHODS
  All patients underwent hormonal evaluations and an oral glucose tollerance test (OGTT) before and after 12 weeks of therapy (Group A (n = 10): myo-inositol 2 gr. plus folic acid 200 mug every day; Group B (n = 10): folic acid 200 mug every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.
  
  
  METHODS
  Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.
  
  
  RESULTS
  After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.
  
  
  CONCLUSIONS
  Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
authors.affiliation: Department of Obstetrics and Gynecology, University of Modena and Reggio Emilia, Italy. algen@unimore.it
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Genazzani
authors.forename: Chiara
authors.initials: C
authors.lastname: Lanzoni
authors.forename: Federica
authors.initials: F
authors.lastname: Ricchieri
authors.forename: Valerio M
authors.initials: VM
authors.lastname: Jasonni
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D001835:Body Weight; D004958:Estradiol / Q000097:blood; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage; D005640:Follicle Stimulating Hormone / Q000097:blood; D005951:Glucose Tolerance Test; D006728:Hormones / Q000097:blood*; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy*; D007294:Inositol / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood; D014463:Ultrasonography
chemical_list: D001786:Blood Glucose; D006728:Hormones; D007328:Insulin; D013739:Testosterone; D007294:Inositol; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D005492:Folic Acid